Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Cancer Res. 2008 Jul 1;68(13):5469–5477. doi: 10.1158/0008-5472.CAN-08-0594

Figure 4.

Figure 4

AR1/2/2b and AR1/2/3/2b are constitutively active. A-C, 22Rv1 cells were transfected with non-targeted control (CTRL) siRNA, or siRNA targeted to Exon 2b. Transfected cells were cultured 24h post-transfection, and subjected to A, Western blot, B cell proliferation assay (*P < 0.05, **P < 0.002, compared to vehicle-treated cells), and C, quantitiative RT-PCR exactly as described in the legends to Figs. 1 and 2. D, DU-145 cells were transfected with expression vectors encoding full-length wild-type AR (AR1-8), AREx1/2/2b, or AREx1/2/3/2b in conjunction with MMTV-LUC or 4XARE-E4-LUC. Cells were treated under serum-free conditions with 1nM mibolerone (Mib) or ethanol (EtOH, vehicle control) for 24h. Luciferase activity was determined. Data represent the mean +/- S.E. from at least three independent experiments, each performed in duplicate. The activity of reporters in the absence of transactivator or androgens was arbitrarily set to 1. Lysates were analyzed by Western blot using an antibody specific for the AR NTD.

HHS Vulnerability Disclosure